Company intelligence / Profile preview

Jiangsu Yayao Biotech

Nanjing, Jiangsu, Chinayayobio.com ↗

Ownership: Private
Development stage: Other

Overview

Jiangsu Yayao Biotech is a private Chinese biotech company focused on the development of small molecule oncology drugs. Its lead asset, YY2201, is an oral ATR inhibitor currently in Phase 1 trials in China for advanced solid tumors. The company has also submitted an IND application in the USA. Another pipeline candidate, XS‑1017, is a preclinical MDM2-p53 interaction inhibitor targeting cancer. No clinical efficacy data have been published as of June 2025.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

YY2201

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Jiangsu Yayao Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Yayao Biotech.